title: Studies on the mechanism of telavancin decreased susceptibility in a laboratory-derived mutant.
abstract: Telavancin is a novel semisynthetic lipoglycopeptide derivative of vancomycin with a dual mode of action. This study sought to understand the mechanisms of decreased telavancin susceptibility in a laboratory-derived Staphlococcus aureus mutant Tlv(DS)MED1952. There were extensive changes in the transcriptome of Tlv(DS)MED1952 compared to the susceptible parent strain MED1951. Genes upregulated included cofactor biosynthesis genes, cell wall-related genes, fatty acid biosynthesis genes, and stress genes. Downregulated genes included lysine operon biosynthesis genes and lrgB, which are induced by telavancin in susceptible strains, agr and kdpDE genes, various cell surface protein genes, phenol-soluble modulin genes, several protease genes, and genes involved in anaerobic metabolism. The decreased susceptibility mutant had somewhat thicker cell walls and a decreased autolytic activity that may be related to decreased proteolytic peptidoglycan hydrolase processing. Membrane fatty acid changes correlated with increased membrane fluidity were observed. It seems likely that there are multiple genetic changes associated with the development of decreased telavancin susceptibility. The Tlv(DS) mutant showed some similar features to vancomycin-intermediate S. aureus and decreased daptomycin susceptibility strains, but also exhibited its own unique features.
authors.affiliation: School of Biological Sciences, Illinois State University, Normal, Illinois 61790-4120, USA.
authors.forename: Yang
authors.initials: Y
authors.lastname: Song
authors.forename: Christopher S
authors.initials: CS
authors.lastname: Lunde
authors.forename: Bret M
authors.initials: BM
authors.lastname: Benton
authors.forename: Brian J
authors.initials: BJ
authors.lastname: Wilkinson
mesh_terms: D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics* / Q000378:metabolism; D002462:Cell Membrane / Q000737:chemistry / Q000187:drug effects; D002473:Cell Wall / Q000737:chemistry / Q000187:drug effects; D017576:Daptomycin / Q000494:pharmacology; D020869:Gene Expression Profiling; D015964:Gene Expression Regulation, Bacterial / Q000187:drug effects*; D000077427:Lipoglycopeptides; D008560:Membrane Fluidity / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics / Q000378:metabolism; D059467:Transcriptome / Q000235:genetics; D014640:Vancomycin / Q000494:pharmacology*; D020713:Vancomycin Resistance / Q000187:drug effects / Q000235:genetics*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D000077427:Lipoglycopeptides; D014640:Vancomycin; D017576:Daptomycin; C487637:telavancin
references.citation: Antimicrob Agents Chemother. 2011 Sep;55(9):4012-8
references.pmid: 21709105
references.citation: Nat Rev Microbiol. 2009 Sep;7(9):629-41
references.pmid: 19680247
references.citation: J Bacteriol. 2011 Nov;193(21):6020-31
references.pmid: 21908676
references.citation: Antimicrob Agents Chemother. 1992 Mar;36(3):566-72
references.pmid: 1320363
references.citation: Cell Host Microbe. 2010 Jun 25;7(6):423-4
references.pmid: 20542245
references.citation: Appl Environ Microbiol. 2008 Oct;74(19):5882-90
references.pmid: 18689519
references.citation: Clin Microbiol Rev. 2010 Jan;23(1):99-139
references.pmid: 20065327
references.citation: Nat Rev Microbiol. 2008 Mar;6(3):222-33
references.pmid: 18264115
references.citation: J Antibiot (Tokyo). 2004 May;57(5):326-36
references.pmid: 15303493
references.citation: Microbiology (Reading). 2003 Oct;149(Pt 10):2719-2732
references.pmid: 14523105
references.citation: PLoS One. 2011 Feb 28;6(2):e17054
references.pmid: 21386961
references.citation: Trends Biochem Sci. 1998 Apr;23(4):143-8
references.pmid: 9584618
references.citation: Antimicrob Agents Chemother. 2011 Feb;55(2):526-31
references.pmid: 21115796
references.citation: J Bacteriol. 1993 Apr;175(8):2400-6
references.pmid: 8468298
references.citation: Appl Environ Microbiol. 2005 Sep;71(9):5171-6
references.pmid: 16151101
references.citation: PLoS Pathog. 2012 Feb;8(2):e1002505
references.pmid: 22319446
references.citation: Antimicrob Agents Chemother. 1986 Feb;29(2):250-7
references.pmid: 2872855
references.citation: Antimicrob Agents Chemother. 2011 Mar;55(3):1082-7
references.pmid: 21173172
references.citation: Antimicrob Agents Chemother. 2011 Aug;55(8):3870-81
references.pmid: 21628539
references.citation: Mol Microbiol. 2007 Dec;66(5):1136-47
references.pmid: 17961141
references.citation: Nucleic Acids Res. 2002 Apr 1;30(7):1620-9
references.pmid: 11917023
references.citation: Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24
references.pmid: 19620338
references.citation: J Bacteriol. 2007 Nov;189(22):8257-69
references.pmid: 17827301
references.citation: J Bacteriol. 2007 Oct;189(20):7316-25
references.pmid: 17675373
references.citation: J Appl Microbiol. 2008 Dec;105(6):1973-81
references.pmid: 19120644
references.citation: Antimicrob Agents Chemother. 2012 Jun;56(6):3157-64
references.pmid: 22411615
references.citation: J Bacteriol. 2003 Jan;185(2):610-9
references.pmid: 12511508
references.citation: Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8
references.pmid: 18443115
references.citation: Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34
references.pmid: 15728913
references.citation: J Biol Chem. 2007 Feb 23;282(8):5770-80
references.pmid: 17166853
references.citation: Antimicrob Agents Chemother. 2010 Aug;54(8):3161-9
references.pmid: 20547804
references.citation: Antimicrob Agents Chemother. 2008 Mar;52(3):980-90
references.pmid: 18086846
references.citation: Antimicrob Agents Chemother. 2004 Oct;48(10):3749-57
references.pmid: 15388430
references.citation: Annu Rev Genet. 2008;42:541-64
references.pmid: 18713030
references.citation: Infect Immun. 2000 Jun;68(6):3548-53
references.pmid: 10816510
references.citation: J Bacteriol. 1995 Sep;177(17):5116-21
references.pmid: 7665491
references.citation: Infect Immun. 2011 Jun;79(6):2154-67
references.pmid: 21422185
references.citation: Microbiology (Reading). 2005 Feb;151(Pt 2):615-623
references.pmid: 15699210
references.citation: Microbiology (Reading). 1996 Jun;142 ( Pt 6):1491-1497
references.pmid: 8704988
references.citation: Antimicrob Agents Chemother. 2007 Mar;51(3):1089-91
references.pmid: 17158941
references.citation: J Antimicrob Chemother. 2008 Jan;61(1):169-72
references.pmid: 17993505
references.citation: FEBS Lett. 2002 Mar 6;514(1):74-7
references.pmid: 11904185
references.citation: JAMA. 2007 Oct 17;298(15):1763-71
references.pmid: 17940231
references.citation: Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83
references.pmid: 19470513
references.citation: J Bacteriol. 2005 Mar;187(5):1751-62
references.pmid: 15716447
references.citation: Curr Drug Targets Infect Disord. 2004 Dec;4(4):273-94
references.pmid: 15578969
references.citation: J Exp Med. 2005 Jul 18;202(2):209-15
references.pmid: 16009720
references.citation: Int J Antimicrob Agents. 2006 Jun;27(6):518-24
references.pmid: 16707247